@FiercePharma: New DSM won't make grief an illness. Panel also cuts two proposed diagnoses: RE psychosis, anxiety/depression--NYT. Article | Follow @FiercePharma
> In CEO Shlomo Yanai's last earnings report before the advent of Jeremy Levin (photo), Teva Pharmaceutical Industries ($TEVA) said profit rose 13% to $859 million, on growth in both branded and generic drugs. Report
> Johnson & Johnson ($JNJ) asked the FDA to approve another new use for its anticoagulant drug Xarelto, this time to reduce the risk of stent-related blood clots. Report
> U.K. regulators won't require drug companies to troll the Internet for adverse-event reports, and nor will they be required to monitor social media, except on sites and pages they control. Report
> India's Zydus Cadila is reportedly in buyout talks with Strides Arcolab; the deal would involve Strides' domestic generics business. Report
> Savient Pharmaceuticals posted a bigger-than-expected loss for the first quarter, thanks to high sales-and-marketing costs on its gout drug Krystexxa, which provided 90% of its revenue. Report
> The FDA said Celgene ($CELG) added label warnings to its blood cancer drug Revlimid, cautioning patients and doctors that users bear a higher risk of certain other cancers. Report
> Merck KGaA's cancer drug Erbitux failed a study in colon cancer. Report
> Japanese private equity firm Unison Capital beat out genericsmaker Mylan ($MYL) and other private-equity bidders for drugmaker Showa Yakuhin Kako. Report
Biotech News
@FierceBiotech: Third Rock's Levin calls for teamwork in personalized medicine by @DamianFierce. Report | Follow @FierceBiotech
@RyanMFierce: GSK's pursuit of HGSI has gone hostile as GSK goes directly to HGS investors with $2.6B tender offer. News | Follow @RyanMFierce
> FDA advisers snub Regeneron drug for gout. News
> Support seen for U.S. plan to speed nods for 'breakthrough' drugs. Article
> GSK raises fists in $2.6B hostile bid for Human Genome Sciences. Report
@FierceMedDev: Covidien bought Maya Medical, the maker of a renal denervation treatment, and barely acknowledged it. Item | Follow @FierceMedDev
> Hygieia releases study results for its new hand-held insulin device. Article
> St. Jude armed with FDA approval for Ellipse ICD. Report
> Given Imaging revenue jumps overall, due to Americas PillCam sales. More
> Covidien grabs Maya Medical for $60M-plus. Item
Drug Delivery News
@DamianFierce: The coming onslaught of blockbuster knockoffs could be a huge opportunity for drug delivery companies. News | Follow @DamianFierce
> Charge-changing nanoparticles can help kill resistant bacteria. More
> pSivida gets U.K. nod for behind-the-eye treatment. Article
> Echo's trandsdermal tech gets positive results, TV time. News
> Patent cliff could create need for novel delivery tech. Item
> MonoSol, Midatech tout positive Phase I for insulin film. Story
Biomarkers News
> Targeted therapies need cost-effective biomarkers. More
> DNA changes could predict prostate cancer relapse. Article
> 15-minute test could tag Alzheimer's. Story
> Biosignatures fingerprint tuberculosis and sarcoidosis. Story
And Finally... Aspirin worked as well as warfarin at warding off clots in congestive heart failure patients, a study found. Report